Phase 2b Placebo-Controlled Randomized Study of BPZE1 Intranasal Pertussis Vaccine in Healthy School-Age Children to Assess Immunological Response and Safety of a Single Dose BPZE1 With/Without Coadministration of Tdap (Boostrix™)

Status: Active, no longer recruiting

Phase of Trial: Phase II

Latest Information Update: 03 Jun 2024

Price : $35 ^*

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs BPZE 1 (Primary) ; DTaP vaccine
Indications Pertussis
Focus Adverse reactions; Pharmacodynamics
Acronyms SUPER
Sponsors ILiAD Biotechnologies

Most Recent Events

28 May 2024 Results published in an ILiAD Biotechnologies media release
28 May 2024 According to an ILiAD Biotechnologies media release, company reports positive topline interim results in the SUPER age trial conducted in 366 participants in the United Kingdom, Australia and Costa Rica.
30 Nov 2023 Planned number of patients changed from 600 to 360.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com

Welcome to AdisInsight